Your shopping cart is currently empty

Venadaparib hydrochloride (IDX-1197) is a potent and selective PARP inhibitor exhibiting significant anticancer properties, particularly effective in solid tumor research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $970 | 1-2 weeks | 1-2 weeks |
| Description | Venadaparib hydrochloride (IDX-1197) is a potent and selective PARP inhibitor exhibiting significant anticancer properties, particularly effective in solid tumor research. |
| Targets&IC50 | PARP2:1 nM (IC50), PARP1:1.4 nM (IC50) |
| In vitro | Venadaparib (example 143; 6-10 days) effectively inhibits the growth of MDA-MB-436 and Capan-1 pancreatic cancer cells, with IC50 values of ≤5nM and 50nM[2], respectively. |
| In vivo | In the germline BRCA1-mutated ovarian cancer patient-derived xenograft (PDX) model, oral administration of Venadaparib (IDX-1197) significantly inhibits PAR (>90%) in tumor tissues for up to 24 hours post-dosing and exhibits dose-dependent, potent tumor growth inhibition, surpassing that of the Olaparib treatment group[1]. |
| Synonyms | IDX-1197 hydrochloride |
| Molecular Weight | 442.92 |
| Formula | C23H24ClFN4O2 |
| Cas No. | 1681020-60-9 |
| Smiles | Cl.Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CC(CNC2CC2)C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.